<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aminophylline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aminophylline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aminophylline: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8620" href="/d/html/8620.html" rel="external">see "Aminophylline: Drug information"</a> and <a class="drug drug_patient" data-topicid="10805" href="/d/html/10805.html" rel="external">see "Aminophylline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1056475"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Bronchodilator</span>;</li>
<li>
<span class="list-set-name">Respiratory Stimulant</span>;</li>
<li>
<span class="list-set-name">Theophylline Derivative</span></li></ul></div>
<div class="block don drugH1Div" id="F53462363"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> All dosages expressed as <b>aminophylline.</b> Dose should be individualized based on serum concentrations. Due to longer half-life compared to older patients, the time to achieve steady-state serum concentration is prolonged in neonates; obtain serum theophylline concentration after 48 to 72 hours of therapy (usually 72 hours in neonates); repeat values should be obtained 3 days after each change in dosage or weekly if on a stabilized dosage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Apnea of prematurity:</b> Limited data available: <b>Note:</b> Caffeine citrate is the preferred agent to treat apnea of prematurity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26628729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26628729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 5 to 8 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25389472','lexi-content-ref-12032788','lexi-content-ref-434904','lexi-content-ref-28474588','lexi-content-ref-26141482','lexi-content-ref-Wongsiridej.2021','lexi-content-ref-29673564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25389472','lexi-content-ref-12032788','lexi-content-ref-434904','lexi-content-ref-28474588','lexi-content-ref-26141482','lexi-content-ref-Wongsiridej.2021','lexi-content-ref-29673564'])">Ref</a></span>); in one trial of 61 neonates (birth weight: ≤1,500 g), a loading dose of 8 mg/kg/dose achieved targeted theophylline serum concentrations in more patients compared to a loading dose of 6 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12032788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12032788'])">Ref</a></span>). Begin maintenance dose 8 to 12 hours following loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9259917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9259917'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: IV: Initial: 2 to 6 mg/kg/<b>day</b> divided every 8 to 12 hours; reported range: 2 to 9 mg/kg/day; increased dosages may be indicated as liver metabolism increases; monitor serum concentrations and adjust to achieve targeted concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9259917','lexi-content-ref-25389472','lexi-content-ref-12032788','lexi-content-ref-28474588','lexi-content-ref-19751376','lexi-content-ref-26141482','lexi-content-ref-Wongsiridej.2021','lexi-content-ref-29673564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9259917','lexi-content-ref-25389472','lexi-content-ref-12032788','lexi-content-ref-28474588','lexi-content-ref-19751376','lexi-content-ref-26141482','lexi-content-ref-Wongsiridej.2021','lexi-content-ref-29673564'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment:</b> Dose reduction and frequent monitoring of serum theophylline concentrations are required in neonates with decreased renal function; 50% of dose is excreted unchanged in the urine of neonates.</p></div>
<div class="block dop drugH1Div" id="F133474"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>All dosages expressed as <b>aminophylline</b>; use ideal body weight to calculate dose; adjust dose based on steady-state serum concentrations. Theophylline dose is ~80% of aminophylline dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86ef74e7-b71e-4a0c-b75f-3d17ae271946">Reversible airflow obstruction, acute symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversible airflow obstruction, acute symptoms: Note:</b> The treatment of asthma exacerbations with aminophylline is not supported or recommended by current clinical practice guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Patients who have <b>not received</b> aminophylline or theophylline in the previous 24 hours: IV: 5.7 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Patients who have <b>received</b> aminophylline or theophylline in the previous 24 hours: Obtain serum theophylline concentration prior to administering a loading dose. The loading dose should be calculated as follows:</p>
<p style="text-indent:-2em;margin-left:10em;">Dose = (C desired – C measured) (V<sub>d</sub>)</p>
<p style="text-indent:-2em;margin-left:10em;">C desired = desired serum theophylline concentration</p>
<p style="text-indent:-2em;margin-left:10em;">C measured = measured serum theophylline concentration</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i>
<b>Note:</b> Dosing presented is to achieve a target theophylline concentration of 10 mcg/mL. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum concentration measurements during the first 12- to 24-hour period.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 4 to 6 weeks: IV: 1.9 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 6 to 52 weeks: Continuous IV infusion: Dose (mg/kg/<b>hour</b>) = [(0.008 × age in weeks) + 0.21] divided by 0.8.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 1 to &lt;9 years: Continuous IV infusion: 1 mg/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 9 to &lt;12 years: Continuous IV infusion: 0.9 mg/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents 12 to &lt;16 years (otherwise healthy, nonsmokers): Continuous IV infusion: 0.6 mg/kg/<b>hour</b>; maximum dose: 1,125 mg/<b>day</b> unless serum concentrations indicate need for larger dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents 12 to &lt;16 years (cigarette or marijuana smokers): Continuous IV infusion: 0.9 mg/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥16 years (otherwise healthy, nonsmokers): Continuous IV infusion: 0.5 mg/kg/<b>hour</b>; maximum dose: 1,125 mg/<b>day</b> unless serum concentrations indicate need for larger dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with cardiac decompensation, cor pulmonale, sepsis with multiorgan failure, or shock:</i> Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.25 mg/kg/<b>hour</b>; maximum dose: 500 mg/<b>day</b> unless serum concentrations indicate need for larger dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment based on serum theophylline concentrations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note:</b> Recheck serum theophylline concentrations in 12 hours (ages 1 month to &lt;16 years) or 24 hours (ages ≥16 years) after dose adjustment; concentrations should also be evaluated if adverse effects occur or conditions altering theophylline clearance are present (eg, sustained fever, drug interactions). Adjust dose based on the following serum concentration results:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;9.9 mcg/mL: If tolerated, but symptoms are not controlled, increase infusion rate by ~25%. Recheck serum theophylline concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">10 to 14.9 mcg/mL: Maintain infusion rate if tolerated and symptoms controlled. Recheck serum concentrations at 24-hour intervals. If symptoms not controlled, consider additional medications for management.</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 19.9 mcg/mL: Consider 10% reduction in infusion rate to improve safety margin even if dose is tolerated.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to 24.9 mcg/mL: Decrease infusion rate by ~25%. Recheck serum concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">25 to 30 mcg/mL: Stop infusion for 12 hours (ages 1 month to &lt;16 years) or 24 hours (ages ≥16 years) and decrease subsequent infusion rate by at least 25% even if no adverse effects are present. Recheck serum concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30 mcg/mL: Stop infusion and treat overdose; if resumed, decrease subsequent infusion rate by at least 50%. Recheck serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064763"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 to 3 months: There are no specific dosage adjustments provided in the manufacturer's labeling; consider dose reduction and frequent monitoring of serum theophylline concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months, Children, and Adolescents: No adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51064764"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: Continuous IV infusion: Initial maintenance infusion: 0.25 mg/kg/<b>hour</b>; maximum dose: 500 mg/<b>day</b> unless serum concentrations indicate need for larger dose. Use with caution and monitor serum theophylline concentrations frequently.</p></div>
<div class="block doa drugH1Div" id="F133454"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8620" href="/d/html/8620.html" rel="external">see "Aminophylline: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> All dosages expressed as <b>aminophylline</b>; use <b>ideal body weight</b> to calculate dose (theophylline has limited distribution into body fat); individualize dose based on steady-state serum theophylline concentrations. Theophylline dose is ~80% of aminophylline dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fb363bea-514d-43d6-b5fd-ecb512edc449">Reversible airflow obstruction, acute refractory symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversible airflow obstruction, acute refractory symptoms: Note:</b> Routine use of aminophylline is not recommended for the treatment of acute asthma exacerbations or chronic obstructive pulmonary disease exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2','lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2','lexi-content-ref-GOLD.1'])">Ref</a></span>). Optimal regimen, dose, and therapeutic concentrations are uncertain; refer to institutional protocol.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose: Note:</b> Doses presented are intended to achieve a serum theophylline concentration of ~10 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients who have not received aminophylline or theophylline in the previous 24 hours:</b>
<b>IV:</b> 5.7 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients who have received aminophylline or theophylline in the previous 24 hours:</b>
<b>Note:</b> Loading dose should <b>NOT</b> be given before obtaining a serum theophylline concentration.</p>
<p style="text-indent:-2em;margin-left:8em;">Calculate loading dose based on serum theophylline concentrations, as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Loading dose = (desired serum theophylline concentration − measured serum theophylline concentration) * (V<sub>d</sub>); where V<sub>d</sub> = 0.5 L/kg [Example: (10 mcg/mL (desired) – 5 mcg/mL (measured)) * 0.5 L/kg * 70 kg = 175 mg loading dose].</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose:</b>
<b>Note:</b> Dosing presented is to achieve a target theophylline concentration of 10 mcg/mL. Lower initial doses may be required in patients with reduced theophylline clearance. Adjust dose according to serum theophylline concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults ≤60 years of age: Continuous infusion: <b>IV:</b> 0.5 mg/kg/hour; maximum dose: 1,125 mg/day unless serum theophylline concentrations indicate need for larger dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults &gt;60 years of age: Continuous infusion: <b>IV:</b> 0.38 mg/kg/hour; maximum dose: 500 mg/day unless serum theophylline concentrations indicate need for larger dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiac decompensation, cor pulmonale, sepsis with multiorgan failure, and shock: Continuous infusion: <b>IV:</b> 0.25 mg/kg/hour; maximum dose: 500 mg/day unless serum theophylline concentrations indicate need for larger dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment based on serum theophylline concentrations:</b>
<b>Note:</b> Recheck serum theophylline concentration 24 hours after dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;9.9 mcg/mL: If dosage is tolerated but symptoms are not controlled, increase infusion rate ~25%.</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 14.9 mcg/mL: Maintain infusion rate if dosage is tolerated and symptoms controlled. Recheck serum theophylline concentrations at 24-hour intervals. If symptoms are not controlled and dosage is tolerated, consider adding additional medications to treatment regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">15 to 19.9 mcg/mL: Consider 10% dose reduction in infusion rate to improve safety margin even if dose is tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">20 to 24.9 mcg/mL: Decrease infusion rate by 25% even if no adverse effects present.</p>
<p style="text-indent:-2em;margin-left:4em;">25 to 30 mcg/mL: Stop infusion for 24 hours and decrease subsequent infusion rate at least 25%. If symptomatic, stop infusion and consider whether overdose treatment is indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;30 mcg/mL: Stop infusion and treat overdose; if resumed, decrease subsequent infusion rate at least 50%.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32eb247d-ec8d-425f-b43b-61892c653d97">Dipyridamole- or regadenoson-induced adverse reactions during nuclear cardiac stress testing, reversal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dipyridamole- or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing, reversal (off-label use):</b>
<b> Note:</b> Since adenosine-induced side effects are short lived after discontinuation of the infusion, aminophylline administration is only very rarely required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914678'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 50 to 250 mg administered over 30 to 60 seconds, repeat as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914678'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991529"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988913"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Initial: 0.25 mg/kg/hour; maximum dose: 500 mg/day unless serum theophylline concentrations indicate need for larger dose. Use with caution and monitor serum theophylline concentrations frequently.</p></div>
<div class="block adr drugH1Div" id="F133419"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Diuresis (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, insomnia, irritability, restlessness, seizure, tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin reaction (Thompson 1984), erythema multiforme (Thompson 1984), exfoliative dermatitis (Thompson 1984), skin photosensitivity (Thompson 1984)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Thompson 1984), angioedema (Thompson 1984)</p></div>
<div class="block coi drugH1Div" id="F133432"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to aminophylline, theophylline, ethylenediamine, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Coronary artery disease where cardiac stimulation might prove harmful; peptic ulcer disease.</p></div>
<div class="block war drugH1Div" id="F133416"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Theophylline toxicity: Severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs. Theophylline clearance may be decreased in patients with acute pulmonary edema, heart failure, cor pulmonale, fever (≥102°F for ≥24 hours or lesser temperature elevations for longer periods), hepatic disease, acute hepatitis, cirrhosis, hypothyroidism, sepsis with multiorgan failure, shock, neonates (term and premature), infants &lt;3 months of age with decreased renal function, infants &lt;1 year, elderly &gt;60 years, and patients following cessation of smoking. Consider benefits versus risks and the need for more intensive monitoring in these patients; reduced dosing may be required. If a patient develops signs and symptoms of theophylline toxicity (eg, nausea or persistent, repetitive vomiting), a serum theophylline concentration should be measured immediately and subsequent doses withheld.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiac arrhythmias (excluding bradyarrhythmias); use may exacerbate arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cystic fibrosis: Use with caution in patients with cystic fibrosis; increased theophylline clearance may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); risk of severe and potentially fatal theophylline toxicity is increased. Theophylline clearance is decreased ≥50% in these patients. Dose reduction and frequent monitoring of serum theophylline concentrations are required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism; increased theophylline clearance may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; use may exacerbate peptic ulcer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with seizure disorders; use may exacerbate seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use extreme caution in the elderly; these patients are at greater risk of serious theophylline toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Select dose with caution and with frequent monitoring of concentrations (especially &lt;1 year); rate of clearance is highly variable in these patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not increase dose in response to acute exacerbation of symptoms unless steady state serum theophylline concentration is &lt;10 mcg/mL. As the rate of theophylline clearance may be dose-dependent, an increase in dose based upon a subtherapeutic serum theophylline concentration measurement should be limited to ~25% increase of the previous infusion rate or daily dose.</p></div>
<div class="block foc drugH1Div" id="F133426"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as dihydrate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (10 mL, 20 mL)</p></div>
<div class="block geq drugH1Div" id="F133412"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F133435"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Aminophylline Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $1.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865887"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as dihydrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (10 mL, 20 mL)</p></div>
<div class="block adip drugH1Div" id="F53565244"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Each mg/kg of theophylline administered as a bolus will increase the serum theophylline concentration by an average of 2 mcg/mL.</p></div>
<div class="block admp drugH1Div" id="F52612219"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: For IV administration only. Infusion time is based on indication:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Apnea of prematurity:</i> Neonates: Infuse dose over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7624272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7624272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Reversible airflow obstruction, acute symptoms:</i> Infants, Children, and Adolescents: Infuse loading dose over 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>); elevate extremity.</p></div>
<div class="block adm drugH1Div" id="F133429"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: For IV administration only. Loading doses should be administered IV over 30 minutes. In patients with cor pulmonale, cardiac decompensation, hepatic impairment, patients &gt;60 years of age, or patients taking medications that reduce theophylline clearance, the initial maintenance infusion rate should not exceed 21 mg/hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Off-label use: For reversal of adenosine-, dipyridamole-, or regadenoson-induced adverse events during nuclear cardiac stress testing, administer IV undiluted over 30 to 60 seconds, repeat as necessary. Since adenosine-induced side effects are short lived after discontinuation of the infusion, aminophylline administration is only very rarely required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914678'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do NOT flush the line; gently aspirate extravasated solution, then remove needle/catheter; elevate extremity; apply dry, warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1981'])">Ref</a></span>).</p></div>
<div class="block uicp drugH1Div" id="F14471281"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 1 mg/mL.</p></div>
<div class="block sts drugH1Div" id="F2572957"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F) in original carton. Protect from light. Do not use if discolored or if crystals are present.</p></div>
<div class="block usep drugH1Div" id="F53565348"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute exacerbation symptoms and reversible airflow obstruction associated with asthma, chronic obstructive pulmonary disease (COPD), or other chronic lung diseases as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids (FDA approved in pediatric patients [age not specified] and adults); has also been used for treatment of apnea of prematurity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>The 2007 National Heart, Lung, and Blood Institute Asthma Guidelines and the 2021 Global Initiative for Asthma Guidelines recommend against aminophylline for the treatment of asthma exacerbations because of poor efficacy and safety concerns (GINA 2021; NAEPP 2007).</p></div>
<div class="block mst drugH1Div" id="F133500"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aminophylline may be confused with amitriptyline, ampicillin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F133489"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F133420"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the stimulatory effect of Theophylline Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine.  Management: Consider alternatives to this combination if possible. Theophylline may decrease adenosine efficacy and higher adenosine doses may be required. When using adenosine for diagnostic studies, discontinue theophylline derivatives 5 half-lives prior to test.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May increase the serum concentration of Aminophylline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithyroid Agents: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: May enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, sympathomimetic effects may be increased. Theophylline Derivatives may enhance the hypokalemic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Bromperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cambendazole: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. Management: Seek alternatives to this combination when possible.  If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of both medications.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Theophylline Derivatives. Management: Consider avoidance of this combination. If coadministration is necessary, monitor for increased theophylline serum concentrations and toxicities when combined. Theophylline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Theophylline Derivatives. Management: Consider avoidance of this combination. If coadministration is necessary, consider an empiric theophylline dose reduction to one-third of the original theophylline dose. Monitor for increased theophylline serum concentrations and toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Weak): May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Theophylline Derivatives may enhance the adverse/toxic effect of Doxofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Erythromycin (Systemic). Management: Consider alternatives to this combination. If combined, monitor for increased serum concentrations/toxic effects of theophylline derivatives.Theophylline derivative dose reductions may be needed. Also monitor for reduced erythromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Febuxostat: May increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: May enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, the risk for seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Norfloxacin: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may increase the serum concentration of QuiNINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regadenoson: Aminophylline may enhance the neuroexcitatory and/or seizure-potentiating effect of Regadenoson. Aminophylline may diminish the vasodilatory effect of Regadenoson.  Management: Avoid using aminophylline or other methylxanthines (eg, caffeine) for at least 12 hours prior to the administration of regadenoson. Aminophylline may be administered after regadenoson to diminish adverse events. Monitor for seizures.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Theophylline Derivatives may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfinpyrazone: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopental: Aminophylline may diminish the therapeutic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: May increase the metabolism of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Viloxazine: May increase the serum concentration of Theophylline Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zafirlukast: Theophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F133447"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: Ethanol may decrease theophylline clearance. Management: Monitor theophylline concentrations, particularly when alcohol consumption patterns change.</p>
<p style="text-indent:-2em;margin-left:2em;">Food: Theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef; a high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline. Management: Avoid extremes of dietary protein and carbohydrate intake.</p></div>
<div class="block pri drugH1Div" id="F133436"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Aminophylline is a complex of theophylline and ethylenediamine. Theophylline crosses the placenta. Refer to Theophylline monograph for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53565335"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum theophylline concentrations, heart rate, respiratory rate, number and severity of apnea spells (when used for apnea of prematurity); arterial or capillary blood gases (if applicable); pulmonary function tests. Monitor infusion site.</p></div>
<div class="block rerp drugH1Div" id="F53565245"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Therapeutic concentrations:</p>
<p style="text-indent:-2em;margin-left:2em;">Asthma: 5 to 15 mcg/mL (SI: 27.8 to 83.3 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">Apnea of prematurity: 6 to 12 mcg/mL (SI: 33.3 to 66.6 micromole/L); goal concentration is reduced due to decreased protein binding and higher free fraction.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Guidelines for Drawing Theophylline Serum Concentrations</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left" valign="middle">
<p style="text-indent:0em;text-align:center;">Dosage Form</p></th>
<th align="left" valign="middle">
<p style="text-indent:0em;text-align:center;">When to Obtain Sample<sup>A</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>A</sup>The time to achieve steady-state serum concentration is prolonged in patients with longer half-lives (eg, infants and adults with cardiac or liver failure; see theophylline half-life table). In these patients, serum theophylline concentrations should be drawn after 48 to 72 hours of therapy; may need to obtain concentrations prior to steady-state to assess the patient's current progress or evaluate potential toxicity.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">IV bolus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">30 min after end of 30-min infusion</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">Continuous IV infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">12 to 24 h after initiation of infusion</p></td></tr></tbody></table></div>
<div class="block pha drugH1Div" id="F133415"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Theophylline has two distinct actions; smooth muscle relaxation (ie, bronchodilation) and suppression of the response of the airways to stimuli (ie, non-bronchodilator prophylactic effects). Bronchodilation is mediated by inhibition of two isoenzymes, phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilation effects are mediated through other molecular mechanisms. Theophylline increases the force of contraction of diaphragmatic muscles through enhancement of calcium uptake through adenosine-mediated channels.</p></div>
<div class="block phk drugH1Div" id="F133431"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Theophylline:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Theophylline: ~0.45 L/kg based on ideal body weight; distributes poorly into body fat; V<sub>d</sub> may increase in premature neonates, hepatic cirrhosis, acidemia (uncorrected), elderly, and third trimester of pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Theophylline: ~40%, primarily to albumin; decreased in neonates (due to a greater percentage of fetal albumin), hepatic cirrhosis, acidemia (uncorrected), elderly, third trimester of pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Theophylline: Hepatic via demethylation (CYP 1A2) and hydroxylation (CYP 2E1 and 3A4); forms active metabolites (caffeine and 3-methylxanthine)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Theophylline: Highly variable and dependent upon age, hepatic function, cardiac function, lung disease, and smoking history</p>
<p style="text-indent:-2em;margin-left:4em;">Premature infants, postnatal age 3 to 15 days: 30 hours (range: 17 to 43 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Premature infants, postnatal age 25 to 57 days: 20 hours (range: 9.4 to 30.6 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Term infants, postnatal age 1 to 2 days: 25.7 hours (range: 25 to 26.5 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Term infants, postnatal age 3 to 30 weeks: 11 hours (range: 6 to 29 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 4 years: 3.4 hours (range: 1.2 to 5.6 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 6 to 17 years: 3.7 hours (range: 1.5 to 5.9 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults ≥18 years to ≤60 years (asthma, nonsmoking, otherwise healthy): 8.7 hours (range: 6.1 to 12.8 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Elderly &gt;60 years (nonsmoking, healthy): 9.8 hours (range: 1.6 to 18 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Certain conditions may significantly alter theophylline clearance; severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">Decreased theophylline clearance: Neonates and infants; elderly &gt;60 years; acute pulmonary edema, cor pulmonale; fever (≥102°F for ≥24 hours or lesser temperature elevations for longer periods); heart failure; hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); hypothyroidism; patients following cessation of smoking; sepsis with multiple organ failure; shock; third trimester of pregnancy.</p>
<p style="text-indent:-2em;margin-left:4em;">Increased theophylline clearance: Hyperthyroidism; cystic fibrosis; smoking (ie, marijuana or tobacco).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Within 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Theophylline: Urine (~50% as unchanged drug [Neonates]; ~10% as unchanged drug [Infants &gt;3 months, Adolescents, and Adults])</p></div>
<div class="block phksp drugH1Div" id="F51220237"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased in infants &lt;3 months with decreased renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is decreased by ≥50% in patients with hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clearance is very low in neonates and reaches max values by 1 year of age, remains relatively constant until about 9 years of age, and then slowly decreases by approximately 50% to adult values at about 16 years of age. Renal excretion of unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance is decreased by an average of 30% in patients &gt;60 years.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Significant reduction in theophylline clearance has been reported in women on the 20th day of the menstrual cycle and during the third trimester of pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Smoking: Clearance is increased by smoking (ie, marijuana or tobacco) by ~50% in young adult and ~80% in elderly tobacco smokers. Cessation of smoking for 1 week causes a reduction in theophylline clearance by ~40%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F133438"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Carena | Euphyllin | Phyllocontin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aminofilin | Aminofilina HLB | Aminofilina northia</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Euphyllin | Mundiphyllin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aminocardol | Aminomal | Aminophyllinum | Cardophylin | Euphylin | Filin | Larnox | Restophyllin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aminoslow | Euphyllin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllinum | Euphyllin | Novphyllin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aminofil | Aminofilin | Aminofilina | Aminoima | Aminoliv | Aminotil | Asmafin | Asmapen | Asmofilin | Asmoquinol | Furp aminofilina | Minoton | Pulmodilat | Unifilin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Escophyllin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A mi kang | Phyllocontin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllinum | Euphylin | Farophyllin | Pharophyllin | Syntophyllin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Teofylamin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina | Aminofilina larjan | Aminomal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina | Eufilina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllinum | Euphyllin | Euphyllinum</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Minophylline-n</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aminocont | Aminofylline</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aminophylline PCH | Planphylline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aminophylline kent | Amnivent | Cardophylin | Norphyllin | Pecram | Phyllocontin continus</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Neophyllin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllinum Lek</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin | Aminophyllinum | Diaphyllin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aminofillin | Decafil | Erphafillin | Phyllocontin continus</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Phyllocontin continus</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin | Minophyl | Phyllocontin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aminofil bil | Aminofillina | Aminomal | Aminomal r | Aminophilline | Tefamin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Euphyllin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aminophylline abbott | Aminophylline fujisawa | Aminophylline merck hoei | Aminophylline Nichiiko | Aminophylline Nipro | Aminophylline towa | Aminophylline Tsuruhara | Anephyllin | Apnission | Kyophyllin | Microfillin | Neophyllin | Nichfylin | Novophyllin | Theocardin v</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aminomal r | Phyllocontin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aminophylline huons | Ascontin | Asthcontin | Daihan aminophylline | Jeil aminophylline | Pediatric asthcontin continus</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Phyllocontin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aminofil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllinum | Eufilinas | Euphylin | Euphyllin | Farophyllin | Novphyllin | Pharophyllin | Sophafyllin | Syntophyllin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Euphyllin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllinum | Eifilins | Euphyllin | Farophyllin | Novphyllin | Pharophyllin | Syntophyllin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina | Aminofilina gi | Amofilin | Mino tec</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Macdech | Shree aminophylline | Vinco aminophylline</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina Braun | Aminofyllin amdipharm | Aminophylline life | Aminophylline mercury</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hizon aminophylline | Theofil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aminofil | Aminophylin | Amphyll | Asmolin | Broncophylline | Phyllocontin | Retaphyline</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aminophylinum | Aminophyllinum | Euphyllin darnitsa | Farophyllin | Syntophyllin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina | Aminofilina Braun | Aminofilina Gestafarma | Aminomal | Filotempo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aminofilin | Aminofilina | Aminofilina arena | Aminofilina bioeel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin | Aminophylline escom | Eufillin | Euphyllin | Euphyllin darnitsa | Euphylline</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Euphyllin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Teofyllamin Meda</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllinum | Pharophyllin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amino Patar | Asmalia | Fileen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aminocardol | Carena | Lafiline | Tecar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin | Anpillin | Asiphylline | Cotranlin | Phyllocontin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin | Euphylline</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ago amin | Nest</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina | Larjanfilina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aminofilina | Aminofuni</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aminophyllin | Aminophyllin fresenius | Aminophylline searle | Merck-aminophylline | Micro theophyl ethylenediamine | Mylan aminophylline | Norstan-Ted | Phyllocontin | Sabax aminophylline</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aramino</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9259917">
<a name="9259917"></a>al-Omran A, al-Alaiyan S. Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants. <i>Am J Perinatol</i>. 1997;14(3):147-149. doi:10.1055/s-2007-994116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/9259917/pubmed" id="9259917" target="_blank">9259917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9789698">
<a name="9789698"></a>Altun A, Kirdar C, Ozbay G. Effect of aminophylline in patients with atropine-resistant late advanced atrioventricular block during acute inferior myocardial infarction. <i>Clin Cardiol</i>. 1998;21(10):759-762. doi:10.1002/clc.4960211012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/9789698/pubmed" id="9789698" target="_blank">9789698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASNC.1">
<a name="ASNC.1"></a>American Society of Nuclear Cardiology. Imaging Guidelines for Nuclear Cardiology Procedures: A Report of The American Society of Nuclear Cardiology Quality Assurance Committee. <i>J Nucl Cardiol. </i>2006;13(6):e21-e171.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Aminophylline [prescribing information]. Lake Forest, IL: Hospira Inc; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Aminophylline [prescribing information]. Lake Forest, IL: Hospira Inc; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25389472">
<a name="25389472"></a>Armanian AM, Badiee Z, Afghari R, et al. Prophylactic aminophylline for prevention of apnea at higher-risk preterm neonates. <i>Iran Red Crescent Med J</i>. 2014;16(8):e12559. doi:10.5812/ircmj.12559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/25389472/pubmed" id="25389472" target="_blank">25389472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1483087">
<a name="1483087"></a>Aronson JK, Hardman M, Reynolds DJ. ABC of Monitoring Drug Therapy. Theophylline. <i>BMJ. </i>1992;305(6865):1355-1358.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/1483087/pubmed" id="1483087" target="_blank">1483087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23672674">
<a name="23672674"></a>Barnes PJ. Theophylline. <i>Am J Respir Crit Care Med</i>. 2013;188(8):901-906. doi:10.1164/rccm.201302-0388PP<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/23672674/pubmed" id="23672674" target="_blank">23672674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7624272">
<a name="7624272"></a>Bhatt-Mehta V, Johnson CE, Donn SM, Spadoni V, Schork MA. Accuracy and reliability of dosing equations to individualize theophylline treatment of apnea of prematurity. <i>Pharmacotherapy</i>. 1995;15(2):246-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/7624272/pubmed" id="7624272" target="_blank">7624272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628729">
<a name="26628729"></a>Eichenwald EC; Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of prematurity. <i>Pediatrics</i>. 2016;137(1):10.1542/peds.2015-3757. doi:10.1542/peds.2015-3757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/26628729/pubmed" id="26628729" target="_blank">26628729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Updated 2021. Accessed April 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26914678">
<a name="26914678"></a>Henzlova MJ, Duvall WL, Einstein AJ, et al. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. <i>J Nucl Cardiol</i>. 2016;23(3):606-639. doi:10.1007/s12350-015-0387-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/26914678/pubmed" id="26914678" target="_blank">26914678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10036847">
<a name="10036847"></a>Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics. Part II of a series. <i>J Am Dental Assoc.</i> 1999;130(2):236-251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/10036847/pubmed" id="10036847" target="_blank">10036847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12032788">
<a name="12032788"></a>Hochwald C, Kennedy K, Chang J, et al. A Randomized, Controlled, Double-Blind Trial Comparing Two Loading Doses of Aminophylline. <i>J Perinatol. </i>2002;22(4):275-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/12032788/pubmed" id="12032788" target="_blank">12032788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-434904">
<a name="434904"></a>Jones RA, Baillie E. Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. <i>Arch Dis Child</i>. 1979;54(3):190-193. doi:10.1136/adc.54.3.190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/434904/pubmed" id="434904" target="_blank">434904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14522503">
<a name="14522503"></a>Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). <i>J Am Coll Cardiol.</i> 2003;42(7):1318-1333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/14522503/pubmed" id="14522503" target="_blank">14522503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412710">
<a name="30412710"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2019;74(7):932-987. doi:10.1016/j.jacc.2018.10.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/30412710/pubmed" id="30412710" target="_blank">30412710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed June 22, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141794">
<a name="33141794"></a>Ong J, Van Gerpen R. Recommendations for management of noncytotoxic vesicant extravasations. <i>J Infus Nurs</i>. 2020;43(6):319-343. doi:10.1097/NAN.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/33141794/pubmed" id="33141794" target="_blank">33141794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14766019">
<a name="14766019"></a>Pasnoori VR, Leesar MA. Use of aminophylline in the treatment of severe symptomatic bradycardia resistant to atropine. <i>Cardiol Rev</i>. 2004;12(2):65-68. doi:10.1097/01.crd.0000096418.72821.fa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/14766019/pubmed" id="14766019" target="_blank">14766019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2107985">
<a name="2107985"></a>Ranhosky A, Kempthorne-Rawson J. The Safety of Intravenous Dipyridamole Thallium Myocardial Perfusion Imaging. Intravenous Dipyridamole Thallium Imaging Study Group. <i>Circulation.</i> 1990;81(4):1205-1209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/2107985/pubmed" id="2107985" target="_blank">2107985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28474588">
<a name="28474588"></a>Shivakumar M, Jayashree P, Najih M, et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: a randomized controlled trial. <i>Indian Pediatr</i>. 2017;54(4):279-283. doi:10.1007/s13312-017-1088-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/28474588/pubmed" id="28474588" target="_blank">28474588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30304941">
<a name="30304941"></a>Singleton EL, Le N, Ness GL. Theophylline and caffeine as alternatives during an aminophylline shortage [published online ahead of print October 11, 2018]. <i>Ann Pharmacother</i>. doi:10.1177/1060028018806624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/30304941/pubmed" id="30304941" target="_blank">30304941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19751376">
<a name="19751376"></a>Skouroliakou M, Bacopoulou F, Markantonis SL. Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. <i>J Paediatr Child Health</i>. 2009;45(10):587-592. doi:10.1111/j.1440-1754.2009.01570.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/19751376/pubmed" id="19751376" target="_blank">19751376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8121733">
<a name="8121733"></a>Strauss RE, Wertheim DL, Bonagura VR, Valacer DJ. Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. <i>Pediatrics</i>. 1994;93(2):205-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/8121733/pubmed" id="8121733" target="_blank">8121733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26141482">
<a name="26141482"></a>Tey SL, Lee WT, Lee PL, Lu CC, Chen HL. Neurodevelopmental outcomes in very low birth weight infants using aminophylline for the treatment of apnea. <i>Pediatr Neonatol</i>. 2016;57(1):41-46. doi:10.1016/j.pedneo.2015.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/26141482/pubmed" id="26141482" target="_blank">26141482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6236577">
<a name="6236577"></a>Thompson PJ, Gibb WR, Cole P, Citron KM. Generalised allergic reactions to aminophylline. <i>Thorax</i>. 1984;39(8):600-603. doi:10.1136/thx.39.8.600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/6236577/pubmed" id="6236577" target="_blank">6236577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wongsiridej.2021">
<a name="Wongsiridej.2021"></a>Wongsiridej P, Ngerncham S, Usaha S, Chandranipapongse W, Cressey TR, Bowornkitiwong W. Serum theophylline concentrations in very preterm neonates receiving intravenous aminophylline for apnea. <i>Siriraj Med J</i>. 2021;73(8):526-531.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29673564">
<a name="29673564"></a>Ye C, Miao C, Yu L, et al. Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit. <i>Pediatr Neonatol</i>. 2019;60(1):43-49. doi:10.1016/j.pedneo.2018.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/29673564/pubmed" id="29673564" target="_blank">29673564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1981">
<a name="Zenk.1981"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12572 Version 308.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
